$TENX News

Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

Tenax Therapeutics To Present Results From Phase 3 LEVEL Clinical Trial In Late-Breaking Clinical Science Session At ESC Congress 2026

Cantor Fitzgerald Reiterates Overweight on Tenax Therapeutics, Maintains $35 Price Target

Guggenheim Maintains Buy on Tenax Therapeutics, Raises Price Target to $40

Chardan Capital Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $27

Piper Sandler Maintains Overweight on Tenax Therapeutics, Raises Price Target to $50

Tenax Therapeutics (NASDAQ:TENX) Q1 2026 Slightly Beats EPS, Gears Up for Pivotal Phase 3 Data in Q3

Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tenax Therapeutics Q1 EPS $(0.35) Beats $(0.58) Estimate

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Tenax Therapeutics Appoints Thomas R. Staab II CFO Effective May 11, Replacing Interim CFO McGauley

Tenax Therapeutics Files Prospectus For Offering $300M Securities

Tenax Therapeutics: A Binary Bet With Heavy Downside Likely

Cantor Fitzgerald Initiates Coverage On Tenax Therapeutics with Overweight Rating, Announces Price Target of $35

Guggenheim Maintains Buy on Tenax Therapeutics, Raises Price Target to $34